SCHEMBL11948445

SCHEMBL11948445

Cn1cc(C(=O)C(N)=O)c2ccc(N(CC(=O)OC(C)(C)C)S(=O)(=O)c3cc(Cl)cc(Cl)c3)cc21

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
HCRTR2 O43614 1/20 0.33
RAB9A P51151 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
MAPT P10636 1/20 0.32
TP53 P04637 2/20 0.32
PLAU P00749 1/20 0.32
MCOLN3 Q8TDD5 1/20 0.31
TSHR P16473 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
PTGER1 P34995 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11948434 0.93 PKM (0.36) PKMHSD17B10KMT2AMEN1HCRTR2
SCHEMBL11948447 0.91 HSD17B10 (0.35) PKMHSD17B10KMT2AMEN1HCRTR2
SCHEMBL11948446 0.90 PKM (0.36) PKMHSD17B10KMT2AMEN1HCRTR2
SCHEMBL11948433 0.89 HSD17B10 (0.36) PKMHSD17B10KMT2AMEN1HCRTR2
SCHEMBL11948439 0.88 HSD17B10 (0.37) PKMHSD17B10KMT2AMEN1HCRTR2
SCHEMBL11948448 0.88 ALOX5 (0.37) PKMHSD17B10KMT2ATP53RXFP1
SCHEMBL14088860 0.88 PKM (0.36) PKMHSD17B10KMT2AMEN1HCRTR2
SCHEMBL2845444 0.87 PLAU (0.42) KMT2AMEN1TP53PLAU
SCHEMBL11948449 0.86 TP53 (0.39) KMT2AMEN1PSEN1PSEN2APH1B
SCHEMBL11948440 0.86 TP53 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232312-B2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
US-8232312-B2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 US disclosed
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 PKM 144/4885HSD17B10 1903/4885KMT2A 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.